Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus standard chemotherapy in previously untreated mantle cell lymphoma
2006-004093-27Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in mantle cell lymphoma (MCL), sponsored by Roche. Primary endpoint: Complete response (CR). Started Feb 2007; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2006-004093-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004093-27.